RYZ101 (²²⁵Ac-DOTATATE) ± pembrolizumab in estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced and unresectable or metastatic breast cancer progressing after prior therapy: the Phase 1b/2 TRACY-1 study

RayzeBio, Inc.
5505 Morehouse Drive, Suite 300
San Diego, CA 92121
info@rayzebio.com

Leadership Team
Approach
Pipeline
Careers
Contact

Leadership Team
Approach
Pipeline
Careers
Contact

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using here, or switch them off in .

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Click here to read more about our use of cookies.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!